SMT201400169B - Nuovo composto utile per il trattamento di malattie degenerative e infiammantorie - Google Patents

Nuovo composto utile per il trattamento di malattie degenerative e infiammantorie

Info

Publication number
SMT201400169B
SMT201400169B SM201400169T SM201400169T SMT201400169B SM T201400169 B SMT201400169 B SM T201400169B SM 201400169 T SM201400169 T SM 201400169T SM 201400169 T SM201400169 T SM 201400169T SM T201400169 B SMT201400169 B SM T201400169B
Authority
SM
San Marino
Prior art keywords
degenerative
treatment
inflammatory diseases
compound useful
new compound
Prior art date
Application number
SM201400169T
Other languages
English (en)
Inventor
Javier Blanc
Christel Jeanne Marie Menet
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of SMT201400169B publication Critical patent/SMT201400169B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SM201400169T 2009-06-26 2014-11-10 Nuovo composto utile per il trattamento di malattie degenerative e infiammantorie SMT201400169B (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22068509P 2009-06-26 2009-06-26
US29818810P 2010-01-25 2010-01-25
PCT/EP2010/059067 WO2010149771A1 (en) 2009-06-26 2010-06-25 Novel compound useful for the treatment of degenerative and inflammatory diseases

Publications (1)

Publication Number Publication Date
SMT201400169B true SMT201400169B (it) 2015-01-15

Family

ID=42340530

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201400169T SMT201400169B (it) 2009-06-26 2014-11-10 Nuovo composto utile per il trattamento di malattie degenerative e infiammantorie

Country Status (38)

Country Link
US (2) US8796457B2 (it)
EP (2) EP2792677B1 (it)
JP (1) JP5486084B2 (it)
KR (1) KR101712561B1 (it)
CN (1) CN102459261B (it)
AR (1) AR077221A1 (it)
AU (1) AU2010264635B2 (it)
BR (1) BRPI1014759A2 (it)
CA (1) CA2765988C (it)
CL (1) CL2011003276A1 (it)
CO (1) CO6491039A2 (it)
CR (1) CR20110673A (it)
CY (1) CY1119711T1 (it)
DK (2) DK2445912T3 (it)
DO (1) DOP2011000378A (it)
EA (1) EA020111B1 (it)
ES (2) ES2519170T3 (it)
HK (2) HK1168098A1 (it)
HR (2) HRP20141057T1 (it)
HU (1) HUE034205T2 (it)
IL (1) IL216618A (it)
JO (1) JO3030B1 (it)
LT (1) LT2792677T (it)
MA (1) MA33447B1 (it)
ME (1) ME01916B (it)
MX (1) MX2011013451A (it)
NZ (1) NZ596836A (it)
PE (1) PE20120494A1 (it)
PL (2) PL2792677T3 (it)
PT (2) PT2445912E (it)
RS (1) RS53617B1 (it)
SG (1) SG177359A1 (it)
SI (2) SI2445912T1 (it)
SM (1) SMT201400169B (it)
TW (1) TWI469981B (it)
UY (1) UY32741A (it)
WO (1) WO2010149771A1 (it)
ZA (1) ZA201109502B (it)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
JP6129155B2 (ja) * 2011-04-12 2017-05-17 ライジェル ファーマシューティカルズ， インコーポレイテッド 同種移植片拒絶反応を抑制する方法
SG10201914052TA (en) * 2011-10-11 2020-03-30 Sanofi Biotechnology Compositions for the treatment of rheumatoid arthritis and methods of using same
TWI589299B (zh) * 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
CN104379173A (zh) * 2012-06-22 2015-02-25 加拉帕戈斯股份有限公司 用于治疗炎症的氨基***并吡啶及其药物组合物
CA2922770A1 (en) 2013-09-05 2015-03-12 F. Hoffmann-La Roche Ag Triazolopyridine compounds, compositions and methods of use thereof
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201402070D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
CA2982629C (en) * 2015-04-13 2023-09-05 Galapagos Nv Methods for the treatment of cardiovascular disorders
JP6978098B2 (ja) 2016-07-26 2021-12-08 スーヂョウ ロングバイオテック ファーマシューティカルズ カンパニー リミテッドSuzhou Longbiotech Pharmaceuticals Co., Ltd. 選択的ｊａｋ阻害剤としての化合物、該化合物の塩類および治療への使用
WO2019149244A1 (zh) * 2018-01-31 2019-08-08 南京明德新药研发股份有限公司 Jak抑制剂及其应用
BR112021003206A2 (pt) 2018-08-29 2021-05-25 Regeneron Pharmaceuticals, Inc. métodos e composições para tratar indivíduos com artrite reumatoide
KR20210122810A (ko) 2019-01-31 2021-10-12 사노피 바이오테크놀로지 청소년 특발성 관절염을 치료하기 위한 항 il-6 수용체 항체
CN111072655B (zh) * 2019-12-30 2021-12-10 深圳市坤健创新药物研究院 一种三氮唑并吡啶类化合物及其制备方法和药用组合物与应用
AU2021276656A1 (en) 2020-05-19 2022-11-24 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
US11596612B1 (en) 2022-03-08 2023-03-07 PTC Innovations, LLC Topical anesthetics

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4058243B2 (ja) 1999-01-29 2008-03-05 中外製薬株式会社 軟骨形成促進剤およびインドリン−２−オン誘導体
EP1391211A1 (en) 2001-04-27 2004-02-25 Chugai Seiyaku Kabushiki Kaisha Chondrogenesis promoters
US6514989B1 (en) * 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
CA2487679A1 (en) * 2002-05-30 2003-12-11 Vertex Pharmaceuticals Incorporated Inhibitors of jak and cdk2 protein kinases
ES2264795T3 (es) 2003-02-14 2007-01-16 Pfizer Products Inc. Triazolo-piridinas como compuestos antiinflamatorios.
US20050222171A1 (en) 2004-01-22 2005-10-06 Guido Bold Organic compounds
EP2360474B1 (en) 2004-06-21 2013-07-24 Galapagos N.V. Methods and means for treatment of osteoarthritis
EP1786811A2 (en) 2004-08-18 2007-05-23 Pharmacia & Upjohn Company LLC Triazolopyridine compounds
BRPI0516819A (pt) 2004-10-07 2008-09-23 Warner Lambert Co derivados de triazolopiridina e agentes antibacterianos
GB0515026D0 (en) 2005-07-21 2005-08-31 Novartis Ag Organic compounds
WO2008025821A1 (en) * 2006-08-30 2008-03-06 Cellzome Limited Triazole derivatives as kinase inhibitors
AR066845A1 (es) 2007-06-05 2009-09-16 Takeda Pharmaceutical Derivados de triazolopiridina e imidazopiridina una composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento del cancer
US8053574B2 (en) 2007-07-18 2011-11-08 Novartis Ag Organic compounds
WO2009017954A1 (en) * 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
WO2009027283A1 (en) 2007-08-31 2009-03-05 Merck Serono S.A. Triazolopyridine compounds and their use as ask inhibitors
GB0719803D0 (en) * 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
US20090217316A1 (en) * 2008-02-22 2009-08-27 Binita Gupta Systems and Methods for Advertising Insertion Notification in a Real-Time Streaming Media Service
PE20110063A1 (es) 2008-06-20 2011-02-16 Genentech Inc DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK
WO2010010189A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010187A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
WO2010010184A1 (en) 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
WO2010010186A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010188A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
BRPI1009637A2 (pt) 2009-06-05 2019-04-30 Cephalon, Inc composto, composição e uso de um composto
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物

Also Published As

Publication number Publication date
HRP20141057T1 (en) 2015-03-13
IL216618A0 (en) 2012-02-29
US20150031671A1 (en) 2015-01-29
WO2010149771A1 (en) 2010-12-29
LT2792677T (lt) 2017-07-25
CN102459261B (zh) 2014-11-05
SI2445912T1 (sl) 2014-12-31
ME01916B (me) 2015-05-20
AR077221A1 (es) 2011-08-10
EA020111B1 (ru) 2014-08-29
CL2011003276A1 (es) 2012-08-31
PT2445912E (pt) 2014-11-07
CO6491039A2 (es) 2012-07-31
ES2519170T3 (es) 2014-11-06
KR101712561B1 (ko) 2017-03-06
US9505754B2 (en) 2016-11-29
DOP2011000378A (es) 2012-02-15
AU2010264635B2 (en) 2015-05-07
ES2634325T3 (es) 2017-09-27
KR20120059487A (ko) 2012-06-08
SI2792677T1 (sl) 2017-08-31
EP2792677B1 (en) 2017-04-26
DK2445912T3 (da) 2014-11-10
DK2792677T3 (en) 2017-07-10
UY32741A (es) 2011-01-31
PE20120494A1 (es) 2012-05-17
HRP20171024T1 (hr) 2017-10-06
HUE034205T2 (en) 2018-01-29
EP2445912B1 (en) 2014-08-13
PL2792677T3 (pl) 2017-09-29
JP5486084B2 (ja) 2014-05-07
TW201103937A (en) 2011-02-01
TWI469981B (zh) 2015-01-21
CY1119711T1 (el) 2018-06-27
CR20110673A (es) 2012-02-09
BRPI1014759A2 (pt) 2016-04-19
CN102459261A (zh) 2012-05-16
US20100331359A1 (en) 2010-12-30
CA2765988C (en) 2017-08-29
EA201270076A1 (ru) 2012-08-30
PL2445912T3 (pl) 2015-02-27
MX2011013451A (es) 2012-04-30
MA33447B1 (fr) 2012-07-03
SG177359A1 (en) 2012-02-28
HK1202537A1 (en) 2015-10-02
EP2445912A1 (en) 2012-05-02
ZA201109502B (en) 2012-09-26
EP2792677A1 (en) 2014-10-22
US8796457B2 (en) 2014-08-05
HK1168098A1 (en) 2012-12-21
RS53617B1 (en) 2015-04-30
AU2010264635A1 (en) 2011-12-22
IL216618A (en) 2014-09-30
PT2792677T (pt) 2017-07-06
JO3030B1 (ar) 2016-09-05
NZ596836A (en) 2013-02-22
JP2012530767A (ja) 2012-12-06
CA2765988A1 (en) 2010-12-29

Similar Documents

Publication Publication Date Title
SMT201400169B (it) Nuovo composto utile per il trattamento di malattie degenerative e infiammantorie
SMT201400072B (it) Nuovi composti utili per il trattamento di malattie degenerative e infiammatorie
SMT201600254B (it) Procedimento per la preparazione di idromagnesite
SMAP200900085A (it) 3-imidazolil-indoli per il trattamento di malattieproliferative
BRPI1015569A2 (pt) compostos úteis para o tratamento de doenças degenerativas e inflamatórias.
SMT201400160B (it) Nuove composizioni per il trattamento di cmt e malattie correlate
HK1195311A1 (zh) 用於治療變性疾病和炎性疾病的新化合物
SMT201400165B (it) Composizioni e metodi per il trattamento di sclerosi multipla
SMT201500268B (it) Derivato di 5-idrossipirimidin-4-carbossammide
SMT201600479B (it) Nuove soluzioni terapeutiche per il trattamento di condizioni neuroinfiammatorie
SMT201500123B (it) Dosaggio unitario di apadenoson
IT1398805B1 (it) Procedimento per la produzione di strumenti medicali
IT1392206B1 (it) Apparato per la produzione di spazzole o scope
IT1394292B1 (it) Procedimento per la sintesi di pregabalina
ITMI20080011A1 (it) Procedimento per la preparazione di diacereina
IT1391776B1 (it) Procedimento per la preparazione di dexlansoprazolo
IT1403250B1 (it) Macroapparato per la produzione e il trattamento di gas
IT1406405B1 (it) Molecole peptidiche per il trattamento di patologie mitocondriali
IT1396036B1 (it) Configurazione strutturale di campo cimiteriale
IT1398273B1 (it) Procedimento per la preparazione di 14-bromo daunomicina
IT1393368B1 (it) Metodo per la preparazione di rufinamide
IT1393349B1 (it) Procedimento per la preparazione di rufinamide
IT1391758B1 (it) Procedimento per la preparazione di dexlansoprazolo amorfo
IT1393017B1 (it) Prodotto per il trattamento di infissi.
ITPD20090106A1 (it) Leggio per luoghi di culto